The FT Global Pharmaceutical and Biotechnology Conference, now in its 35th successful year brings together life science companies, their health industry counterparts and emerging new industry entrants to review the key challenges facing the industry, and the business models and transformation strategies that will be needed to survive and thrive in this new era of unprecedented disruption and uncertainty.
FT Global Pharmaceutical and Biotechnology Conference
Thriving amid Uncertainty
The Merck Group
With the Support Of
“This FT conference has become an annual leadership forum on the international stage, it’s a really important event for London and the UK.”
The Rt Hon George Freeman, Minister for Life Sciences UK
“The FT is always at the centre of what goes on in the industry. It’s a great source for all kinds of information and this conference for me is a great way to keep up with the trends and figure out what’s going on in the industry.”
Dr Flemming Ornskov, Chief Executive Officer, Shire
“The FT conference is one of the most important conferences in Europe and it’s a no-brainer that people participate in this event.”
Stefan Oschmann, Vice Chairman of the Executive Board & Deputy CEO, Merck
“Great conference to get an update on the strategic direction of global pharma from senior decision makers.”
Emily Lekkas, Scottish Development International
“A very relevant event for pharma/biotech, investors and industry observers.”
Guy Martin, The Pharma Letter
“The conference offers a tremendous opportunity to learn perspectives and insights on business models and medical value.”
Tim Durham, Takeda Pharmaceuticals
As old world certainties regarding payments, products and patients are swept away in a tidal wave of pricing pressures, growing geopolitical uncertainties and the new world realities of value, data and outcomes, life science companies will need to find new ‘ways to play’ if they are to adapt and compete in the new health economy which is emerging. Opportunities in the prevention, treatment and care of patients across key therapeutic areas including Alzheimer’s, cancer and other diseases of ageing, as well as the burgeoning field of precision medicine present opportunities, but can life science companies successfully play to their strengths in IP, regulation and high science to navigate the new terrain and ensure their place at the table?
Fleming Ornskov assumed the position of Chief Executive Officer in April, 2013 and has been a member of the Board since January, 2013. Dr Ornskov brings to his position his operational and medical knowledge and his extensive international, strategic and operational experience in the pharmaceutical sector. He formerly held the position of Non-Executive Chairman of Evotec AG, and of Non-Executive Director of PCI Biotech Holding ASA. From 2010 to 2012 he was Chief Marketing Officer and Global Head, Strategic Marketing for General and Specialty Medicine at Bayer. Prior to this, from 2008 to 2010, Dr Ornskov served as Global President, Pharmaceuticals and OTC at Bausch & Lomb, Inc. He also served as Chairman, and later as President and Chief Executive Officer, of Life-Cycle Pharma A/S from 2006 to 2008, and President and Chief Executive Officer of Ikaria, Inc. from 2005 to 2006. Earlier in his pharmaceutical career Dr Ornskov had roles of increasing responsibility at Merck & Co., Inc. and Novartis AG, following a distinguished period spent in hospitals and academic medicine. He received his MD from the University of Copenhagen, MBA from INSEAD, and Master of Public Health from Harvard University.
Mr Christian Hogg, has been an Executive Director and Chief Executive Ofﬁcer of Hutchison China MediTech Limited since 2006. He is also a member of the Technical Committee of the Company. He joined Hutchison China in 2000 and has since led all aspects of the creation, implementation and management of the Company’s strategy, business and listing. This includes the creation of the Company’s start-up businesses and the acquisition and operational integration of assets that led to the formation of the Company’s China joint ventures. Prior to joining Hutchison China, Mr Hogg spent ten years with P&G starting in the US in Finance and then Brand Management in the Laundry and Cleaning Products Division. Mr Hogg then moved to China to manage P&G detergent business followed by a move to Brussels to run P&G global bleach business. Mr Hogg received a Bachelor’s degree in Civil Engineering from the University of Edinburgh and an MBA from the University of Tennessee.
José Luis Molinuevo
Sarah Haywood became Chief Operating Officer of MedCity in October 2014, after fulfilling the role in an acting capacity since its launch in April 2014 alongside her position as Head of Life Sciences at London & Partners, and was appointed CEO in December 2015.
She is a graduate of the NHS Management Training Scheme in Wales and started her career in the NHS, working in a number of Trusts, including Great Ormond Street NHS Foundation Trust, before joining Novartis Pharmaceuticals Research as Head of Operations for a neuroscience drug discovery unit.
From there, she joined the civil service and undertook a number of roles as a member of the Senior Civil Service, including leading the DTI (now BIS) Bioscience Unit before it became part of the Office for Life Sciences. Her last role in BIS was leading the design and legislation for the extension of the right to request flexible working and the shared parental leave system. In January 2014 she joined London & Partners where she worked with Dr Eliot Forster to establish MedCity.
Ms Haywood has a degree in Biology from the University of Oxford, a post graduate diploma in management and an MA in human resources management; she is a chartered fellow of the Chartered Management Institute.
Sir Andrew Dillon
Sir Andrew Dillon joined the NHS in 1975 and held a number of senior management positions, including General Manager of the Royal Free Hospital and Chief Executive of St George’s Healthcare NHS Trust, before joining the National Institute for Health and Clinical Excellence as its founding Chief Executive in 1999.
Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Office, and was appointed Chairman of the Board of Directors in 2015. Prior to joining Incyte, Mr Hoppenot was the President of Novartis Oncology, where he was responsible for translational medicine, development, approval and commercialisation, which included $11bn in global sales, the largest oncology pipeline in the industry, and a workforce of 8,000 employees in 50 countries. Mr Hoppenot joined Novartis in 2003 and, in addition to his role as President, served as Chief Commercial Officer, Head of Global Product Strategy & Scientific Development, and Senior Vice President, Head of Global Marketing. He started his career in 1983 with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the US Oncology business unit. Mr Hoppenot holds a Diploma from ESSEC Business School.
Rod MacKenzie, is Executive Vice President, Chief Development Officer for Pfizer. In this role, he is responsible for the development and advancement of Pfizer’s pipeline of medicines in several therapeutic areas, including cardiovascular and metabolic disease, inflammation and immunology, neuroscience, oncology and rare disease. He serves on the Portfolio Strategy and Investment Committee, which focuses on maximising the return on R&D investment across the Pfizer portfolio, and is a member of Pfizer’s Executive Leadership Team.
Dr MacKenzie joined Pfizer in Sandwich, UK as a Research Scientist. He is the co-inventor of darifenacin (Enablex™). Dr MacKenzie has held numerous leadership positions at Pfizer, including Head of PharmaTherapeutics Research and Development. He also served as Site Director of the Groton, Connecticut laboratories, Pfizer’s largest global R&D facility. Prior to this role, Dr MacKenzie held a series of research leadership positions, including Senior Vice President and Head of Worldwide Research, Head of Discovery Chemistry in Sandwich, UK, Head of the Discovery Technology Center in Cambridge, Massachusetts, Head of Discovery Research in Ann Arbor, Michigan, and Head of Drug Safety R&D.
Dr MacKenzie represents Pfizer on the Board of Directors for ViiV Healthcare, a global specialist HIV company established by GlaxoSmithKline and Pfizer to deliver advances in treatment and care for people living with HIV.Dr MacKenzie graduated from the University of Glasgow with a 1st Class Honours degree in chemistry and completed his PhD at Imperial College, London.
Andrew Thompson is Co-Founder, President and Chief Executive Officer of Proteus Digital Health. His vision for digital medicines is focused on expanding global access to care, dramatically increasing the value delivered by drugs and creating a sustainable model for innovation that leverages the cell phone in everyone's pocket. He is also a Co-Founder and Board Member of Summit Schools, a leading Charter High School organization with an acclaimed track record and unique digital platform, featured in the Davis Guggenheim movie Waiting for Superman.
Mr Thompson is active in digital humanities innovation with Stanford University and Cambridge University and a Co-Founder of Parker Library Online – the leading destination for digital medieval studies. He holds masters degrees in Engineering (Cambridge), Education (Stanford) and Business (Stanford GSB) and has a successful 25 year track record starting and building technology based healthcare companies in Silicon Valley.
Francesco De Rubertis
Bahija Jallal is Executive Vice President of AstraZeneca and Head of MedImmune, a global biologics research and development organization with locations in Gaithersburg, California and Cambridge, UK. She is a member of the senior executive team at AstraZeneca reporting to the CEO. She joined MedImmune in March 2006. In addition to her roles at AstraZeneca, Dr Jallal is a member of the Board of Directors of the University of Maryland Health Sciences Research Park Corporation, a non-profit organisation that manages biomedical research development at the University’s BioPark. She was recently appointed to the Board of Trustees of The Johns Hopkins University. Dr Jallal has authored over 70 peer-reviewed publications and has over 15 patents. She is a member of the American Association of Cancer Research, the American Association of Science and the Pharmacogenomics Working Group. She serves as a member of the Board of Directors for the Association of Women in Science and an advisory board member of the Healthcare Business Women’s Association. She was named one of Fierce Biotech’s "Women in Biotech" and a "Women Who Mean Business" from the Washington Business Journal. In 2013, Dr Jallal earned the Grace Award from Cancer Research Institute. Prior to joining MedImmune, Dr Jallal worked with Chiron Corporation where she served as Vice President, Drug Assessment and Development, and successfully established the company’s translational medicine group. Prior to Chiron Corporation, she worked at Saugeen, Inc. where she held positions of increasing responsibility leading to Senior Director, Research. Dr Jallal received a Master’s degree in Biology from the Universite de Paris VII in France, and her doctorate in physiology from the University of Pierre & Marie Curie in Paris. She conducted her postdoctoral research at the Max-Planck Institute of Biochemistry in Martinsried, Germany.
Dmitry Kaminskiy is an innovative entrepreneur and investor who is active in the fields of biotech, fintech, blockchain and artificial intelligence. He is Co-founder and Senior Partner at the Hong Kong based investment fund, Deep Knowledge Ventures, which focuses on disruptive exponential technologies and globally known as the first company to appoint artificial intelligence on its board of directors.
Mr Kaminskiy is a leading visionary in the field of ultra-innovative technologies and one of the founders of the Exponential Technologies Institute. In addition to his business experience, he is involved in several scientific endeavours. He strongly believes in the fact that humans should live longer healthier lives. His biggest interest is anti-aging and healthy longevity, which he has engaged in business, research, and public activities. Mr Kaminskiy is well known for his support of life extension think-tanks in Oxford and Cambridge and many other non-profit activities. His one million dollar prize for the first person to reach their 123th birthday went viral, and was covered by the world’s top media.
Professor Guido Rasi was appointed as Principal Adviser in Charge of Strategy of the European Medicines Agency in 2014. Prior to this, from 2011 to 2014 he was the Executive Director, and from 2008 to 2011 a Member of its Management Board of the Agency. He also held the post of Director-General of the Italian Medicines Agency from 2008 to 2011, and was a member of the Agency’s Management Board from 2004 and 2008. This followed a prior career in academia. Professor Rasi was appointed Professor of Microbiology at the University of Rome 'Tor Vergata' in 2008. From 2005 to 2008 he was Director of the Institute of Molecular Medicine of the National Research Council in Rome and from 1990 to 2005, he worked at the Institute for Experimental Medicine of the National Research Council, Italy. He also had teaching and research experience at the University of California, Berkeley in 1999. Professor Rasi holds a degree in Medicine and Surgery, with specialisations in Internal Medicine, Allergology and Clinical Immunology from the University of Rome. From 1978 to 1990, he worked as a physician in hospital based, research and private practice. He is author of more than 100 scientific publications.
Chairs and Moderators (2)
David Crow is a Senior US Business Correspondent for the Financial Times, covering telecoms, technology, and pharmaceuticals. He is based in New York. He previously worked on the FT's main news desk in London, where he edited the front page of the print edition. Before joining the FT he was Managing Editor of City AM, the London financial newspaper.
Mr Crow has an MA in English Literature from the University of Glasgow.
Sarah Neville began her career on local and regional newspapers, eventually becoming political editor of the Yorkshire Post. In 1995 she was awarded the Laurence Stern Fellowship on the Washington Post. She joined the Financial Times in 2001 and has since held a series of senior roles, including Weekend News Editor, Analysis Editor, UK News Editor and public policy editor in 2011. She was appointed Pharmaceuticals Correspondent in 2016.
Agenda - 9th Nov
9:00amOpening remarks from the Chair
9:30am‘Way to Play’: Embracing Strategic Opportunities in the New Health Economy
The recent history of pharma has been one of significant value destruction. Returns for shareholders look set to become in increasingly commensurate with those from commoditised industries – a position forecast only to intensify as pricing and other industry pressures start of bite. New ways to create value will need to be found if the industry is to continue to win favour with investors and strategies will need to be defined which will enable them to compete, to adapt and to embrace many of the new opportunities emerging in the new health economy. From high science, high premium and digitally enhanced business models to strategies based on developing off-the-shelf IP acquired from big pharma, what are the ‘ways to play’ to create value and growth in life sciences? What are the risk and opportunities in the various approaches?
Bélén Garijo, Member of the Board and CEO, Healthcare, The Merck Group
Jeremy Levin, Chairman and CEO, Ovid Therapeutics
10:10amGetting the Big Picture: Geopolitical and Economic Risk-What Lies Ahead?
From the backlash against globalisation and its impact on trade and global integrated supply chains to the decline economic growth and structural challenges in emerging markets-what is the industry vulnerability to geopolitical risk, and the macroeconomic exposure it faces? What are the external forces currently at play which will add considerably to the industry exposure to risk?
10:30amPanel: Trumpcare: What next for US Healthcare Reform?
With a new Administration in Washington pledging to overhaul the nation’s healthcare system, what will it mean for the life sciences and broader healthcare industry? Will we see Republicans successfully coalesce around an alternative healthcare reform proposal which will achieve the reported objectives of delivering improved choice, access and lower costs for patients? What will changes regarding insurance coverage, tax, immigration policies payment reform, trade and support for biomedical research, for instance, mean for the industry? What lies ahead for US healthcare reform in the months and years ahead, and how are healthcare and life science companies addressing this uncertainty?
Kevin Pojasek, Vice President, Director of Corporate Strategy, Immunocore Limited
11:10amNetworking Coffee Break
11:25amPanel: Adopting Open Innovation-Location, Strategies, Risks
Open innovation continues as a core strategy for life science companies in their drive to increase the productivity of their R&D. Location is key to the success of such efforts. For years, big pharma has been situated in fortress-like corporate campuses in places like New Jersey, Indiana and the Chicago suburbs. But increasingly, drugmakers are moving scientists to biotech clusters in coastal America and in Cambridge, UK. Here they can be close to the world's leading academic centres and younger drugmakers, guaranteeing access to early-stage science. What makes these "clusters" tick and what are the new hot areas to watch? Are clusters the best way to achieve enhanced collaboration? What are the opportunities, challenges and risks (e.g. IP) of open innovation? What are the lessons from early adapters and the outcomes?
Gabriel Baertschi, CEO, Grünenthal
Sarah Haywood, Chief Executive Officer, MedCity
12:05pmRight Sizing Regulation
As the debate regarding regulation moves centre stage with calls increasing for a loosening of regulation, speakers will discuss the pros and cons of less onerous regulation and drug approval. Are we seeing a politicisation of the debate of the drug approval process, with standards compromised and regulators ceding to patient pressures? As research breakthroughs continue to advance the boundaries of what’s possible in treatments, can we expect more coordinated campaigns as desperate patients strive to bend the regulatory rules rule in their favour? Or does regulation require a fundamental rethink? Should the focus be on safety, with efficacy left to doctors and patients?
Professor Guido Rasi, Executive Director, European Medicines Agency (EMA)
Vada Perkins, Founder and Managing Principal, IDENTIFICA Global Regulatory Consultancy
1:50pmPricing and Access
Concerns regarding pricing and access remain central to the industry’s future profitability and sustainability. What are the emerging developments with regards to pricing, and potential solutions to the current impasse? Will self-regulation be sufficient? Will regulators, payers and patients continue to reward innovation?
Deborah Waterhouse, CEO, ViiV Healthcare
Sir Andrew Dillon, Chief Executive Officer, NICE
2:30pmRealising the Potential of Real World Evidence (RWE)
As pharma companies continue to grapple with RWE, we hear from leaders in this field, who have developed end-to-end RWE capabilities, with insights into emerging best practice, and views on the remaining challenges in realising the full potential of RWE.
Andy Schmeltz, Senior Vice President, Patient & Health Impact, Pfizer
Andrew Thompson, Founder, President and Chief Executive Officer, Proteus Digital Health
3:10pmTransforming Clinical Trials to move them to a 21st Century Paradigm
Rod MacKenzie, Executive Vice President, Chief Development Officer, Pfizer
3:30pmPanel: Focus on Cancer
Given recent high profile knockbacks in trial results, what is the outlook for the burgeoning immuno-oncology space? Will the hopes for solutions in cancer combination therapies be realised? What are the prospects and challenges for emerging cancer therapies, to include CAR-T? As the level of competition in cancer therapies increases, will the field become increasingly commoditised? How could a growing focus on prevention, rather than cure impact financing and research on cancer?
Arie Belldegrun, Founder, Executive Chairman, Chief Executive Officer and President, Kite Pharma
Andre Choulika, Chairman and Chief Executive Officer, Cellectis
3:50pmThe Trouble with Alzheimer’s: Transforming Treatment, Prevention and Care
Dementia-an ‘unstoppable epidemic, with Alzheimer’s at its core-is a leading cause of mortality in both the developed and developing world, and the enticing economics of ageing populations is drawing growing numbers of in pharmaceutical and healthcare compapaies into finding solutions the improve the treatment prevention and care of the disease. Yet progress has been slow, with no new treatments in a decade and recent drugs hailed to have promise failing in clinical trials. With the amyloid plaque theory now in doubt, is it time to evaluate alternative approaches, and which central theory is likely to guide further research efforts? Should the focus of research and investment now move to prevention? What are the innovations in diagnostics and technologies (e.g. robotics. AI.IoT, telecare etc.). prevention and care which could revolutionise the field?
Session Keynote: Vivek Ramaswamy, Chief Executive Officer, Roivant Sciences
Amit Roy, Founding Partner, Foveal
Henry Mahncke, Chief Scientific Officer, Posit Science
José Luis Molinuevo, Scientific Director, Barcelona Beta Brain Research Centre, Pasqual Maragall Foundation
4:30pmInvestor Panel: How do the Markets View the Future for the Industry?
In this final session of the day, our panel of leading investment bankers, venture capitalists and private equity specialists, and industry analysts share their views on how they see the sector changing and the potential headwinds and opportunities ahead.
Ori Hershkovitz, Founder/CIO, NEXTHERA Capital
Francesco De Rubertis, Co-Founder, Medicxi
5:10pmEnd of Day One
Agenda - 10th Nov
9:00amOpening remarks from the Chair
Flemming Ornskov, Chief Executive Officer, Shire
9:30amPanel: Strategy Forum
In this session, our panel of Heads of Strategy /Chief Strategy Officers of leading pharma companies share their views on the megatrends ahead with the potential to further transform the industry.
Stephen Moran, Global Head of Strategy, Novartis
10:10amPanel: How Will Precision Medicine Transform Healthcare and Life Sciences?
Precision medicine-the tailoring of medicine and healthcare to a person’s individual’s genes, lifestyle and environment- is making steady inroads, but how can the full potential of precision medicine be better harnessed, and its economic model and utility enhanced? With the more accurate diagnostics and the more precise disease classification precision medicine enables, what are the inplicatiions for drug research and for healthcare systems currently built around disease specific specialisations? As geneticists and computational experts take on a greater role, what will be the role for the physician? With more tailored and indivualised treatments, will life science companies successfully embrace opportunities emerging along the’ patient journey’? With the transition to value-based care models expedite the uptake of precision medicine?
Herve Hoppenot, President and Chief Executive Officer, Incyte Corp
Bahija Jallal, Executive Vice President, AstraZeneca and Head, MedImmune
11:00amFood as Medicine
As an understanding of the link between food and health and the role of the microbiome grows, food companies are moving into the field of therapeutic and personalised nutrition, and behaving increasing like drug companies through a focus on regulated products. What are the implications for life science companies? To what extent are these developments a threat or an opportunity to pharma? What are the prospects for personalised nutrition products based on gene/ biome type? Will food become a normal part of prescribing alongside pharmaceutical products?
Lihl Segal, Co-Founder and CEO, DayTwo
11:40amNetworking Coffee Break
11:45amSocial Prescribing - The Next Big Thing?
With social prescribing playing an ever greater role in the medical professional’s toolbox, what are the implications for pharma? What is the evidence of the impact of social prescribing on health outcomes? Should health services pay? Will traditional drug based therapies and adherance be compromised, with detrimental impacts on health?
Stacy Lindau,Founder and Chief Innovation Officer, NowPow
12:30pmAging and Longevity
A growing number of healthcare companies and investment capital is making its way into the study of aging with the aim not only of extending healthspan -but also of studying the link between the processes of aging with a view to halting the onset of and the many diseases which afflict old age to include Alzheimer's, heart disease and chronic diseases such as diabetes. What lies ahead could be a future in which aging could be viewed as just another disease to be ‘cured’, resulting in a less crippling and costly burden from age-related drug development and for care within the healthcare system. How far along are we in better understanding aging, and when might we see the testing and potential approval of anti-aging drugs in humans? What are the practical and philosophical challenges which need to be addressed before the development of anti-aging drugs arrives in earnest?
Dmitry Kaminsky, Co-Founder and Senior Partner, Deep Knowledge Ventures
1:10pmDisrupt or Be Disrupted: The Big Digital Debate
Will pharma companies flourish or flounder in the new digitised healthcare world which is emerging? While pharma companies are recognising the value of digital products and services, their initiatives to date can appear as isolated beacons in a sea of change sweeping the healthcare industry. Will the industry be upended by data and consumer savvy new entrants who are impinging even into the core R&D business of pharma? Or will the industry traditional strengths in R&D, IP, risk management and complexity set them apart from the competition? Can they own and successfully navigate ‘the last mile’ to the customers ensure their place as winners in the hew health economy which is emerging?
Adam Hill, Chief Medical Officer, McLaren Applied Technologies
1:40pmClosing Remarks from the Chair
1:45pmClose of Conference
- Review the diverse strategies life science companies are adopting to position themselves for growth and to navigate the emerging value and outcomes terrain
- Debate the potential to greater cross-industry and cross-sector collaboration in the race for faster, cheaper, better cures
- Hear from those who are turning the vision of personalised medicine into a clinical reality for patients today, and their views on the challenges ahead
- Discover how leading life science companies are managing economic uncertainty to capitalise on the value of high-potential emerging markets
- Gain critical insights in to new commercial models of pharma - what’s working and not working as value and personalisation upend traditional sales and marketing models
- Don’t get left behind - be part of a must-attend event mapping the continued transformation of healthcare
- Hear how life sciences are competing, adapting and embracing strategic opportunities in the new health economy.
- Deep dive on the trouble with Alzheimer's and review the solutions to transforming treatment, prevention and care.
- Learn the latest on food as medicine - what is the opportunity and the challenge for pharma?
- Join the debate on how to right size regulation as the push for faster drug approval and less onerous regulation gains momentum
- Discover how precision medicine will transform healthcare and life sciences
- Disrupt or be disrupted: as digital gains steam will pharma flourish or flounder?
FT Live has a reputation for delivering very senior board level audiences to attend a wide range of world class thought-leadership events across the globe for nearly 40 years.
The FT Global Pharmaceutical and Biotechnology Conference will be attended by:
- Pharmaceutical companies
- Biotechnology companies
- Diagnostic and medical devices
- Healthcare providers and insurers
- Government healthcare departments, HTA’s and drug regulators
- Digital health companies
- Genomics and personalised medicine experts
- IT, big data and analytics providers
- Health economists
- Healthcare investment bankers, private equity and venture capitalists
- Healthcare lawyers and management consultants
- Patient representatives and NGOs
Presented By (1)
The Financial Times is one of the world’s leading business news organisations, recognised internationally for its authority, integrity and accuracy. Providing essential news, comment, data and analysis for the global business community, the FT has a combined paid print and digital circulation of 840,000. Mobile is an increasingly important channel for the FT, driving more than half of total traffic.
With the Support Of (1)
About Life Sciences and Health Care at Deloitte*
Deloitte’s life sciences and health care (LSHC) industry group is composed of over 12,000 professionals in over 90 countries. These professionals understand the complexity of today’s life sciences and health care industry challenges, and provide clients with integrated, comprehensive services that meet their respective needs. In today’s environment, LSHC professionals from across the Deloitte network help companies to evolve in a changing marketplace, pursue new and innovative solutions, and sustain long-term profitability.
*Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited (DTTL), a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity.
Lead Sponsor (1)
ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, and to government. The company specialises in the strategic development, management and analysis of programs that support clinical development. ICON offers a full range of consulting, development and commercialisation services that help clients to accelerate the development of drugs and devices that save lives and improve quality of life.
ICON has built a reputation as an industry innovator and expert in transforming pharma R&D through strategic partnerships and alliances. The company’s expertise in managing and interpreting large clinical and real-world data sets has led to its selection by organisations involved in key transformative projects, including the 100,000 Genomes Project, the world’s largest genome sequencing project for cancer and rare diseases. ICON has also been chosen by the International Consortium for Health Outcomes Measurement (ICHOM) to advance value-based healthcare through the creation of the world’s first global healthcare outcomes benchmarking program.
With headquarters in Dublin, Ireland, ICON currently operates from 88 locations in 37 countries and has approximately 12,600 employees. For further information please visit www.iconplc.com. Follow @iconplc on Twitter.
Associate Sponsor (1)
Pfizer is one of the world’s premier innovative biopharmaceutical companies, discovering, developing and providing over 120 different medicines, vaccines and consumer healthcare products to help save and improve the lives of millions of people in the UK and around the world every year.
Supporting Partners (4)
Established in 1986, the Pharmafocus brand continues to be the most read and respected news portal in the pharmaceutical and biotech industry, with a team of dedicated journalists constantly updating the website; pharmafile.com, monthly newspaper Pharmafocus and daily e-newsletters with the latest quality global news, thoroughly researched analysis, market intelligence and high profile interviews. Covering important issues affecting the industry from the early stages of drug development, clinical trials, manufacturing, market access and global logistics.
PharmaBoardroom.com’s detailed country-specific reports - Healthcare and Life Sciences Review - deliver up an engaging mix of insight, opinion and market intelligence straight from the corporate boardrooms of some of the world’s most high performance economies.
Download our latest country report on
Biotechgate is a global, comprehensive, life science database covering the Biotech, Pharma and Medtech industries. There are currently over 45,000 company profiles on the Biotechgate database. Biotechgate is commonly used to find product pipelines, collaboration partners, in/out-licensing opportunities and information about technology platforms, management details, new business leads and financing rounds. In addition, our licensing deals database supports companies in negotiating their licensing agreements.
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 33 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.
222 Marylebone Road
London NW1 6JQ
United KingdomTel: +44 (0) 20 7631 8000